Related Experiment Video
Updated: Dec 24, 2025

06:37
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
972
Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)
Florent Wallet1,2, Emmanuel Bachy3,4, Olivia Vassal5,3
1Medical Intensive Care Unit, Hospices Civils de Lyon, Lyon Sud Teaching hospital, 165, chemin du Grand-Revoyet, 69495, Pierre-Bénite cedex, France. Florent.wallet@chu-lyon.fr.
Bone Marrow Transplantation
|April 12, 2020
Abstract
No abstract available in PubMed .
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
382
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
382
The JAK-STAT Signaling Pathway
11.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.5K

